Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates

Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or... Osteoporos Int (2017) 28:2701–2705 DOI 10.1007/s00198-017-4080-6 ORIGINAL ARTICLE Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates 1,2 1 1 B. Uebelhart & R. Rizzoli & S. L. Ferrari Received: 28 November 2016 /Accepted: 4 May 2017 /Published online: 24 May 2017 International Osteoporosis Foundation and National Osteoporosis Foundation 2017 Abstract to BPs (mean exposure 6.9 ± 5.8 years, range 11 months– Summary Discontinuation of denosumab (Dmab) therapy is 15 years; mean time interval between BP exposure and associated with lower serum CTX levels in osteoporotic pa- Dmab initiation 25 ± 10 months, range 0–48). In contrast, in tients previously exposed to bisphosphonates compared to 12 patients who discontinued Dmab after multiple (5, range 3– those who were not. 9) injections without prior exposure to BPs, mean CTX levels Introduction Discontinuation of Dmab therapy is followed by as measured on average 11.3 months (range 6–23) after the a transient increase of bone turnover markers (BTMs) above last Dmab injection were above the upper limit of premeno- pretreatment values, together with accelerated bone loss, and pausal range (mean +114%, range 28–320%, p =0.003–0.005 potentially an increased risk of multiple vertebral fractures. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Osteoporosis International Springer Journals

Retrospective evaluation of serum CTX levels after denosumab discontinuation in patients with or without prior exposure to bisphosphonates

Loading next page...
 
/lp/springer_journal/retrospective-evaluation-of-serum-ctx-levels-after-denosumab-YxZtddn70N
Publisher
Springer London
Copyright
Copyright © 2017 by International Osteoporosis Foundation and National Osteoporosis Foundation
Subject
Medicine & Public Health; Orthopedics; Endocrinology; Rheumatology
ISSN
0937-941X
eISSN
1433-2965
D.O.I.
10.1007/s00198-017-4080-6
Publisher site
See Article on Publisher Site

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 12 million articles from more than
10,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Unlimited reading

Read as many articles as you need. Full articles with original layout, charts and figures. Read online, from anywhere.

Stay up to date

Keep up with your field with Personalized Recommendations and Follow Journals to get automatic updates.

Organize your research

It’s easy to organize your research with our built-in tools.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

Monthly Plan

  • Read unlimited articles
  • Personalized recommendations
  • No expiration
  • Print 20 pages per month
  • 20% off on PDF purchases
  • Organize your research
  • Get updates on your journals and topic searches

$49/month

Start Free Trial

14-day Free Trial

Best Deal — 39% off

Annual Plan

  • All the features of the Professional Plan, but for 39% off!
  • Billed annually
  • No expiration
  • For the normal price of 10 articles elsewhere, you get one full year of unlimited access to articles.

$588

$360/year

billed annually
Start Free Trial

14-day Free Trial